טוען...

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems

Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities. The combination with a safer drug can be a strategy in reducing dosage and toxicity while incre...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Chang, Jo-Fan, Hsu, Jui-Ling, Sheng, Yi-Hua, Leu, Wohn-Jenn, Yu, Chia-Chun, Chan, She-Hung, Chan, Mei-Ling, Hsu, Lih-Ching, Liu, Shih-Ping, Guh, Jih-Hwa
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2019
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6344441/
https://ncbi.nlm.nih.gov/pubmed/30705876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00681
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!